Screener / SEC EDGAR /CIK 0001865782 /10-K filed Feb 27, 2026, compared with Mar 6, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Home Health Care Services

BrightSpring Health Services, Inc. BTSG

Compare with peers Embed

BTSG among the 162 companies we cover

Where it stands · the better end on the right. The band holds the middle half; the line is the median.

All 162
Sales growth
+4.8%+20.2%
+28.2%30th of 155 · median +10.5%
Net margin
-4.1%15.3%
2.7%93rd of 154 · median 6.8%
Return on equity
-5.2%18.5%
18.8%36th of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
3.2%103rd of 145 · median 10.0%
Debt / equity (less is better)
1.160.42
1.0076th of 108 · median 0.69

BTSG and 9 peers, year by year

The 9 Health care companies closest to BTSG in revenue over the last twelve months. Every number is from the 10-K and links to it in SEC's Inline XBRL viewer.

Choose the peers

Health care companies (up to 9):

Each company's latest fiscal year
CompanyYearRevenueSales growthGross marginOperating marginNet marginFCF marginReturn on equityDebt / equity
BTSG BrightSpring Health Services, Inc. FY2025 $12.9B+28.2%11.8%2.3%1.5%3.1%10.2%1.34
VTRS Viatris FY2025 $14.3B−3.0%35.1%−18.6%−24.6%13.5%−23.9%0.98
LH Labcorp FY2025 $14.0B+7.2%28.8%9.9%6.3%8.6%10.2%0.65
DVA DaVita FY2025 $13.6B+6.5%-15.0%5.5%9.6%n/mn/m
HSIC Henry Schein FY2025 $13.2B+4.0%31.1%5.0%3.0%4.3%12.3%0.96
REGN Regeneron Pharmaceuticals FY2025 $14.3B+1.0%-24.9%31.4%28.4%14.4%0.06
TEVA Teva Pharmaceutical Industries Ltd FY2025 $17.3B+4.3%51.8%12.5%8.2%6.7%17.8%2.12
IQV IQVIA FY2025 $16.3B+5.9%-13.4%8.3%12.6%20.9%2.42
VRTX Vertex Pharmaceuticals FY2025 $12.0B+8.9%-34.8%32.9%26.6%21.2%0.00
UHS Universal Health Services FY2025 $17.4B+9.7%-11.5%8.6%4.9%20.5%0.66

Each company, year by year

Bars: revenue, each company on its own scale. Line: net margin, on one scale for all. FY2022 to FY2025 · 10-K XBRL

BTSGBrightSpring Health Services, Inc.
FY2022 revenue $7.7BFY2023 revenue $7.7BFY2024 revenue $10.1BFY2025 revenue $12.9B FY2022 net margin −0.7%FY2023 net margin −2.0%FY2024 net margin −0.2%FY2025 net margin 1.5% FY2022FY2025
Revenue$12.9B Growth+28.2% Net margin1.5%
VTRSViatris
FY2022 revenue $16.3BFY2023 revenue $15.4BFY2024 revenue $14.7BFY2025 revenue $14.3B FY2022 net margin 12.8%FY2023 net margin 0.4%FY2024 net margin −4.3%FY2025 net margin −24.6% FY2022FY2025
Revenue$14.3B Growth−3.0% Net margin−24.6%
LHLabcorp
FY2022 revenue $11.9BFY2023 revenue $12.2BFY2024 revenue $13.0BFY2025 revenue $14.0B FY2022 net margin 10.8%FY2023 net margin 3.4%FY2024 net margin 5.7%FY2025 net margin 6.3% FY2022FY2025
Revenue$14.0B Growth+7.2% Net margin6.3%
DVADaVita
FY2022 revenue $11.6BFY2023 revenue $12.1BFY2024 revenue $12.8BFY2025 revenue $13.6B FY2022 net margin 4.8%FY2023 net margin 5.7%FY2024 net margin 7.3%FY2025 net margin 5.5% FY2022FY2025
Revenue$13.6B Growth+6.5% Net margin5.5%
HSICHenry Schein
FY2022 revenue $12.6BFY2023 revenue $12.3BFY2024 revenue $12.7BFY2025 revenue $13.2B FY2022 net margin 4.3%FY2023 net margin 3.4%FY2024 net margin 3.1%FY2025 net margin 3.0% FY2022FY2025
Revenue$13.2B Growth+4.0% Net margin3.0%
REGNRegeneron Pharmaceuticals
FY2022 revenue $12.2BFY2023 revenue $13.1BFY2024 revenue $14.2BFY2025 revenue $14.3B FY2022 net margin 35.6%FY2023 net margin 30.1%FY2024 net margin 31.1%FY2025 net margin 31.4% FY2022FY2025
Revenue$14.3B Growth+1.0% Net margin31.4%
TEVATeva Pharmaceutical Industries Ltd
FY2022 revenue $14.9BFY2023 revenue $15.8BFY2024 revenue $16.5BFY2025 revenue $17.3B FY2022 net margin −16.4%FY2023 net margin −3.5%FY2024 net margin −9.9%FY2025 net margin 8.2% FY2022FY2025
Revenue$17.3B Growth+4.3% Net margin8.2%
IQVIQVIA
FY2022 revenue $14.4BFY2023 revenue $15.0BFY2024 revenue $15.4BFY2025 revenue $16.3B FY2022 net margin 7.6%FY2023 net margin 9.1%FY2024 net margin 8.9%FY2025 net margin 8.3% FY2022FY2025
Revenue$16.3B Growth+5.9% Net margin8.3%
VRTXVertex Pharmaceuticals
FY2022 revenue $8.9BFY2023 revenue $9.9BFY2024 revenue $11.0BFY2025 revenue $12.0B FY2022 net margin 37.2%FY2023 net margin 36.7%FY2024 net margin −4.9%FY2025 net margin 32.9% FY2022FY2025
Revenue$12.0B Growth+8.9% Net margin32.9%
UHSUniversal Health Services
FY2022 revenue $13.4BFY2023 revenue $14.3BFY2024 revenue $15.8BFY2025 revenue $17.4B FY2022 net margin 5.0%FY2023 net margin 5.0%FY2024 net margin 7.2%FY2025 net margin 8.6% FY2022FY2025
Revenue$17.4B Growth+9.7% Net margin8.6%

Who rewrote the most

Share of the words changed in Risk Factors and in MD&A, latest 10-K against the one before

Risk FactorsMD&AEach company's latest 10-K, so the dates differ. A company that rewrote much may have reorganized the text.

Revenue, FY2022 to FY2025

Revenue as reported in the 10-K.

100 FY2022FY2023FY2024FY2025 VTRS: $16.3B, $15.4B, $14.7B, $14.3B VTRS LH: $11.9B, $12.2B, $13.0B, $14.0B LH DVA: $11.6B, $12.1B, $12.8B, $13.6B DVA HSIC: $12.6B, $12.3B, $12.7B, $13.2B HSIC REGN: $12.2B, $13.1B, $14.2B, $14.3B REGN TEVA: $14.9B, $15.8B, $16.5B, $17.3B TEVA IQV: $14.4B, $15.0B, $15.4B, $16.3B IQV VRTX: $8.9B, $9.9B, $11.0B, $12.0B VRTX UHS: $13.4B, $14.3B, $15.8B, $17.4B UHS BTSG: $7.7B, $7.7B, $10.1B, $12.9B BTSG
BTSG is the bold green line; each peer has its own colour and dash, named at the line's end. Each company's first year in the window is 100, on a log scale: a line twice as high has doubled. A gap is a year with no number. BTSG: the line is cut where a later 10-K restates the year before (a spin-off or a merger), so the two years are not the same company.

Sales growth, FY2022 to FY2025

Revenue against the fiscal year before.

−24.3% +31.0% FY2022FY2023FY2024FY2025 VTRS: −9.0%, −5.1%, −4.5%, −3.0% VTRS LH: −9.7%, +2.5%, +7.0%, +7.2% LH DVA: −0.1%, +4.6%, +5.6%, +6.5% DVA HSIC: +2.0%, −2.4%, +2.7%, +4.0% HSIC REGN: −24.3%, +7.8%, +8.3%, +1.0% REGN TEVA: −6.0%, +6.2%, +4.4%, +4.3% TEVA IQV: +3.9%, +4.0%, +2.8%, +5.9% IQV VRTX: +17.9%, +10.5%, +11.7%, +8.9% VRTX UHS: +6.0%, +6.6%, +10.8%, +9.7% UHS BTSG: -, +14.3%, +31.0%, +28.2% BTSG
BTSG is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −24.3% to +31.0%. A gap is a year with no number. A ring marks where a line starts: BTSG has no earlier 10-K here.

Gross margin, FY2022 to FY2025

Gross profit / revenue.

11.8% 51.8% FY2022FY2023FY2024FY2025 VTRS: 40.0%, 41.7%, 38.2%, 35.1% VTRS LH: 31.3%, 27.7%, 27.9%, 28.8% LH HSIC: 30.3%, 31.3%, 31.7%, 31.1% HSIC TEVA: 46.7%, 48.2%, 48.7%, 51.8% TEVA BTSG: 17.5%, 14.8%, 12.6%, 11.8% BTSG
BTSG is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from 11.8% to 51.8%. A gap is a year with no number.
CompanyFY2022FY2023FY2024FY2025
BTSG Dec 17.5%14.8%12.6%11.8%
VTRS Dec 40.0%41.7%38.2%35.1%
LH Dec 31.3%27.7%27.9%28.8%
DVA Dec ----
HSIC Dec 30.3%31.3%31.7%31.1%
REGN Dec ----
TEVA Dec 46.7%48.2%48.7%51.8%
IQV Dec ----
VRTX Dec ----
UHS Dec ----
Peer median35.6%36.5%34.9%33.1%

Operating margin, FY2022 to FY2025

Operating income / revenue.

−18.6% 48.2% FY2022FY2023FY2024FY2025 VTRS: 9.9%, 5.0%, 0.1%, −18.6% VTRS LH: 12.1%, 6.0%, 8.4%, 9.9% LH DVA: 11.5%, 13.2%, 16.3%, 15.0% DVA HSIC: 5.9%, 5.0%, 4.9%, 5.0% HSIC REGN: 38.9%, 30.9%, 28.1%, 24.9% REGN TEVA: −14.7%, 2.7%, −1.8%, 12.5% TEVA IQV: 12.5%, 13.2%, 14.3%, 13.4% IQV VRTX: 48.2%, 38.8%, −2.1%, 34.8% VRTX UHS: 7.5%, 8.2%, 10.6%, 11.5% UHS BTSG: 2.4%, 0.8%, 1.1%, 2.3% BTSG
BTSG is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −18.6% to 48.2%. A gap is a year with no number.

Net margin, FY2022 to FY2025

Net income / revenue.

−24.6% 37.2% FY2022FY2023FY2024FY2025 VTRS: 12.8%, 0.4%, −4.3%, −24.6% VTRS LH: 10.8%, 3.4%, 5.7%, 6.3% LH DVA: 4.8%, 5.7%, 7.3%, 5.5% DVA HSIC: 4.3%, 3.4%, 3.1%, 3.0% HSIC REGN: 35.6%, 30.1%, 31.1%, 31.4% REGN TEVA: −16.4%, −3.5%, −9.9%, 8.2% TEVA IQV: 7.6%, 9.1%, 8.9%, 8.3% IQV VRTX: 37.2%, 36.7%, −4.9%, 32.9% VRTX UHS: 5.0%, 5.0%, 7.2%, 8.6% UHS BTSG: −0.7%, −2.0%, −0.2%, 1.5% BTSG
BTSG is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −24.6% to 37.2%. A gap is a year with no number.

Free cash flow, FY2022 to FY2025

Cash from operations minus capital spending.

−$790.3M $4.4B FY2022FY2023FY2024FY2025 VTRS: $2.6B, $2.5B, $2.0B, $1.9B VTRS LH: $1.5B, $874.1M, $1.1B, $1.2B LH DVA: $961.1M, $1.5B, $1.5B, $1.3B DVA HSIC: $506.0M, $353.0M, $700.0M, $573.0M HSIC REGN: $4.4B, $3.9B, $3.7B, $4.1B REGN TEVA: $1.0B, $842.0M, $749.0M, $1.1B TEVA IQV: $1.6B, $1.5B, $2.1B, $2.1B IQV VRTX: $3.9B, $3.3B, −$790.3M, $3.2B VRTX UHS: $262.0M, $524.7M, $1.1B, $849.2M UHS BTSG: −$74.8M, $137.3M, −$57.1M, $394.7M BTSG
BTSG is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −$790.3M to $4.4B. A gap is a year with no number.

FCF margin, FY2022 to FY2025

Free cash flow / revenue.

−7.2% 44.0% FY2022FY2023FY2024FY2025 VTRS: 15.9%, 16.4%, 13.4%, 13.5% VTRS LH: 12.9%, 7.2%, 8.4%, 8.6% LH DVA: 8.3%, 12.3%, 11.4%, 9.6% DVA HSIC: 4.0%, 2.9%, 5.5%, 4.3% HSIC REGN: 36.3%, 29.5%, 25.8%, 28.4% REGN TEVA: 7.0%, 5.3%, 4.5%, 6.7% TEVA IQV: 11.0%, 10.0%, 13.7%, 12.6% IQV VRTX: 44.0%, 33.8%, −7.2%, 26.6% VRTX UHS: 2.0%, 3.7%, 7.1%, 4.9% UHS BTSG: −1.0%, 1.8%, −0.6%, 3.1% BTSG
BTSG is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −7.2% to 44.0%. A gap is a year with no number.

Return on equity, FY2022 to FY2025

Net income / shareholders' equity at the year end.

−31.3% 78.7% FY2022FY2023FY2024FY2025 VTRS: 9.9%, 0.3%, −3.4%, −23.9% VTRS LH: 12.7%, 5.3%, 9.3%, 10.2% LH DVA: 78.7%, 65.5%, n/m, n/m DVA HSIC: 15.6%, 11.4%, 11.5%, 12.3% HSIC REGN: 19.1%, 15.2%, 15.0%, 14.4% REGN TEVA: −31.3%, −7.4%, −30.5%, 17.8% TEVA IQV: 18.9%, 22.2%, 22.6%, 20.9% IQV VRTX: 23.9%, 20.6%, −3.3%, 21.2% VRTX UHS: 11.4%, 11.7%, 17.1%, 20.5% UHS BTSG: −7.1%, −26.4%, −1.1%, 10.2% BTSG
BTSG is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −31.3% to 78.7%. A gap is a year with no number.

Debt / equity, FY2022 to FY2025

Total debt / shareholders' equity at the year end.

0.00 12.53 FY2022FY2023FY2024FY2025 VTRS: 0.91, 0.89, 0.75, 0.98 VTRS LH: 0.53, 0.64, 0.79, 0.65 LH DVA: 12.53, 7.95, n/m, n/m DVA HSIC: 0.33, 0.64, 0.75, 0.96 HSIC REGN: 0.09, 0.08, 0.07, 0.06 REGN TEVA: 2.72, 2.64, 3.31, 2.12 TEVA IQV: 2.21, 2.24, 2.30, 2.42 IQV VRTX: -, -, -, 0.00 VRTX UHS: 0.81, 0.80, 0.68, 0.66 UHS BTSG: -, 5.75, 1.58, 1.34 BTSG
BTSG is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from 0.00 to 12.53. A gap is a year with no number. A ring marks where a line starts: BTSG, VRTX have no earlier 10-K here.
CompanyFY2022FY2023FY2024FY2025
BTSG Dec -5.751.581.34
VTRS Dec 0.910.890.750.98
LH Dec 0.530.640.790.65
DVA Dec 12.537.95n/mn/m
HSIC Dec 0.330.640.750.96
REGN Dec 0.090.080.070.06
TEVA Dec 2.722.643.312.12
IQV Dec 2.212.242.302.42
VRTX Dec ---0.00
UHS Dec 0.810.800.680.66
Peer median0.860.840.750.81

EPS (diluted), FY2022 to FY2025

Diluted earnings per share, on today's share count after splits.

−$3.00 $41.48 FY2022FY2023FY2024FY2025 VTRS: $1.71, $0.05, −$0.53, −$3.00 VTRS LH: $13.97, $4.77, $8.84, $10.46 LH DVA: $5.85, $7.42, $10.73, $9.84 DVA HSIC: $3.91, $3.16, $3.05, $3.27 HSIC REGN: $38.22, $34.77, $38.34, $41.48 REGN TEVA: −$2.20, −$0.50, −$1.45, $1.21 TEVA IQV: $5.72, $7.29, $7.49, $7.84 IQV VRTX: $12.82, $13.89, −$2.08, $15.32 VRTX UHS: $9.14, $10.23, $16.82, $23.10 UHS BTSG: −$0.46, −$1.31, −$0.09, $0.87 BTSG
BTSG is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −$3.00 to $41.48. A gap is a year with no number.

Fiscal years are lined up as each company's 10-K names them; the month next to a ticker is when its year ends. Hover a number for the XBRL line items and the filing; click it to open the filing on sec.gov. "n/m" means not meaningful: equity below zero, or a base so close to zero that the ratio says nothing. The peer median leaves out BTSG and needs at least three peers with the number. P/E, P/S and P/FCF at each year end appear here once the site has daily prices. What the same companies write about AI, tariffs and more

Sources

Each company's 10-K, from SEC's XBRL company facts. Every number links to its filing in the Inline XBRL viewer.

Also

Financials: BTSG's own statements, year by year. Compare: the whole peer group on one page.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BTSG/export.csv") into a cell.

Next:Industry numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.